Eklira®/Bretaris® Genuair® (aclidinium bromide) Approved in Europe for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD) – PR Newswire

Almirall S.A. (ALM) announced today that the European Commission has granted marketing approval to Eklira/Bretaris Genuair ® (aclidinium 322µg twice daily) in all EU member states, plus Iceland and Norway, as a maintenance bronchodilator treatment to …

Leave a Reply

Your email address will not be published. Required fields are marked *